Along with this study, very recently, Barreira da Silva et al. showed that inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10 and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3 (80). Here, CXCR3 is linked to neoplasm.